Investigators concluded that the spiked samples from SeraCare were a robust tool for inter-lab comparisons and discussed some areas of discordance seen in the study.
The firm will use the proceeds to scale operations, advance its companion diagnostics program, and further expand its minimal residual disease program.
At the AACR meeting, Elaine Mardis detailed efforts at Nationwide Children's Hospital to sequence patients' DNA and RNA to help inform therapeutic decisions.
ArcherDX plans to keep its research and development efforts in its current facility and move its clinical and commercial testing operations to Baby Gene's CLIA lab.
Archer will develop and pursue regulatory approval for a companion diagnostic that will help find patients who may benefit from one of Merck's drug candidates.
The team performed anchored multiplex PCR-based next-generation sequencing on 26 genes linked to sarcomas, comparing the method to standard diagnostic tools.
